SIBN

AI Memo

SI-BONE

As of 2026-09-18/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Higher inpatient reimbursement takes effect • 2026-10-01

Base target: $22 / p=50% prob

Biggest risk

Clearance or launch delays, weak initial utilization, or failure to translate physician growth into territory productivity could undermine the thesis. SI-BONE remained GAAP loss-making in Q2, and multiple August-September open-market sales by the CEO, operating/financial chief and a director temper sentiment without proving operating deterioration. [#SEC-FORM4-2026-08-21] [#SEC-FORM4-2026-08-26] [#SEC-FORM4-2026-09-03]

Invalidation

Break below $14 or thesis failure.

What would change my mind?

Approximately 15% revenue and procedure growth, 19% physician-base expansion, positive adjusted EBITDA and operating cash flow, improved reimbursement, and a pending breakthrough-device launch create several identifiable growth levers. [#SEC-8K-2026-08-03]

Research note

Recommendation

—

Confidence

high

As of

2026-09-18

Base target

$22

p=50%

Bull target

$27

p=25%

Bear target

$14

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Growth and profitability follow-through
Procedure and physician-base expansion
Approximately 15% revenue and procedure growth, 19% physician-base expansion, positive adjusted EBITDA and operating cash flow, improved reimbursement, and a pending breakthrough-device launch create several identifiable growth levers.

BearKey bullets

A 79.5% Q2 gross margin was slightly below 79.8% a year earlier, while operating expenses rose 7.7% amid commercial activity and product rollout.
[#SEC-8K-2026-08-03]
Recent open-market sales by senior executives and a director create a sentiment overhang, though the supplied Form 4 evidence does not establish motive or a change in business conditions.

WatchKey bullets

Higher inpatient reimbursement takes effect

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $22 (p=50%)

Target spread vs base: +23% / -36%

Scenario probabilities

Bull Target: $27 (p=25%)Base Target: $22 (p=50%)Bear Target: $14 (p=25%)

Commentary

Primary evidence is constructive: Q2 showed mid-teens growth, improving adjusted profitability, positive operating cash flow, raised guidance, a pending launch and a favorable reimbursement change. However, recent news coverage is thin, social coverage is unavailable, and no reliable options-skew, short-interest, employee-score or post-print analyst-revision data were supplied; the zero values denote unavailable inputs rather than neutral readings. Insider sales and the decline from transaction prices near $19-$20 to the $18.04 anchor warrant monitoring.

As of 2026-09-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Growth and profitability follow-through
Procedure and physician-base expansion

Scenarios

Bull Target (Scenario probability)

$27 / p=25% prob

Base Target (Scenario probability)

$22 / p=50% prob

Bear Target (Scenario probability)

$14 / p=25% prob

Analysis 2026-09-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-01
Higher inpatient reimbursement takes effect
CMS finalized a new MS-DRG family providing higher payments for complex spinal-fusion procedures incorporating iFuse Bedrock Granite, effective October 1, 2026. Improved hospital economics could support adoption, although the revenue effect remains unquantified. [#SEC-8K-2026-08-03]
Prob 90.00% • Move 7.00% • Priced-in 65.00%
EVENT2026-12-31
Third breakthrough-device clearance and phased launch
SI-BONE submitted a 510(k) application in June for its first platform outside the pelvis and expected, subject to clearance, a phased fourth-quarter 2026 launch potentially beginning in October. Clearance timing and early surgeon uptake are the principal near-term product catalysts. [#PR-EARNINGS-2026-08-11]
Prob 70.00% • Move 12.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Growth and profitability follow-through
2026-11-15
Q2 revenue reached $56.0 million, adjusted EBITDA was positive at $2.8 million, operating cash flow was positive at $0.8 million, and management raised 2026 guidance. Subsequent results must demonstrate that product-rollout spending can coexist with continued operating leverage. [#SEC-8K-2026-08-03]
Prob 65% • Move 9% • Priced-in 55%

Long-term Catalysts

Months to a year

Procedure and physician-base expansion
2027-06-30
Second-quarter worldwide revenue grew 15.2%, U.S. procedure volume grew 14.9%, and the active U.S. physician base increased 19%. Sustaining these gains while converting broader physician engagement into productive utilization would support multi-year growth. [#SEC-8K-2026-08-03]
Prob 65% • Move 15% • Priced-in 45%

Risks

A 79.5% Q2 gross margin was slightly below 79.8% a year earlier, while operating expenses rose 7.7% amid commercial activity and product rollout. [#SEC-8K-2026-08-03]
Recent open-market sales by senior executives and a director create a sentiment overhang, though the supplied Form 4 evidence does not establish motive or a change in business conditions. [#SEC-FORM4-2026-08-21] [#SEC-FORM4-2026-08-26] [#SEC-FORM4-2026-09-03]
SI-BONE reported a $4.1 million Q2 net loss despite improved adjusted EBITDA, so durable GAAP profitability remains unproven. [#SEC-8K-2026-08-03]
The available peer set is loose, and missing analyst-count and post-earnings revision data reduce confidence in valuation benchmarking.
The third breakthrough device remains subject to 510(k) clearance, making launch timing and commercial contribution uncertain. [#PR-EARNINGS-2026-08-11]

Peers

Symbol	Summary
ABT	Abbott provides broad medtech context for hospital demand, reimbursement and product launches, but its diversification and much larger scale limit comparability with SI-BONE.
BSX	Boston Scientific is a profitable, diversified medical-device comparator for commercial execution and new-product adoption, but its scale and cardiovascular focus make direct valuation comparison weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-18

Loading AI feed…

Symbol

Summary

ABT

Abbott provides broad medtech context for hospital demand, reimbursement and product launches, but its diversification and much larger scale limit comparability with SI-BONE.

BSX

Boston Scientific is a profitable, diversified medical-device comparator for commercial execution and new-product adoption, but its scale and cardiovascular focus make direct valuation comparison weak.